Talk:Gevokizumab
Jump to navigation
Jump to search
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Gevokizumab.
|
Copied and pasted from other sources
This article seems to be directly C&Pd from various sources, including company websites and press releases. E.g. http://www.servier.com/content/servier-initiates-phase-2-study-gevokizumab-patients-diabetic-nephropathy and http://www.fiercebiotech.com/r-d/xoma-crushed-as-lead-drug-flunks-a-phiii-challenge
The clue is in the language... "a potent mAb... with unique properties", "In July 2015 the drug suffered a Phase III failure in patients with Behçet's disease uveitis was a bust."
Cloning jedi (talk) 12:02, 11 July 2016 (UTC)